Analysis Life Sciences Thank You How have pre-submission meetings for generic drug applicants changed under GDUFA III?
Agency IQ
MAY 17, 2024
Ultimately, industry is wagering that increased regulatory efficiency—which it pays for—will benefit its products through faster review times, more certainty and more time on the market for its products. GDUFA III), which reauthorized the program through 2027. The generic drug user fee program is currently on its third iteration (i.e.,
Let's personalize your content